Phage products company Micreos revealed on Tuesday that it has received FDA & USDA approval for Phageguard-E as a 'GRAS' (Generally Recognized as Safe) food processing aid against E.coli O157.
Based in the Netherlands, the company's new PhageGuard-E product consists of natural phages against E.coli and the product is produced in Europe.
In conjunction with the US FDA approval, PhageGuard-E, a new surface intervention to combat E. coli O157 on food products, will now be available for the US beef industry. Micreos, a pioneer in targeted pathogen reduction technology, plans to start industrial scale projects with US meat processing companies shortly.
The company said the recent research conducted at the University of Neveda demonstrated superior results of PhageGuard-E surface spray on E. coli O157 contaminated fresh cold beef over currently used chemicals. The findings are of particular interest to beef processors looking for natural and effective post harvest interventions, reducing E. coli O157 on beef carcasses, primals, subs and trimmings.
Unlike harsh chemical interventions, phages are harmless to plant workers and do not damage equipment, concrete floors and water-treatment installations. Unlike traditional chemical treatments, PhageGuard-E kills E. coli without affecting the organoleptic properties of treated food products, concluded the company.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial